Here are the S-3 shelf registrations from Myriad Genetics Inc (MYGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow MYGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYGN filings page.
Myriad Genetics is registering up to $200,000,000 of securities for sale from time to time. This shelf prospectus, dated February 24, 2026, covers common stock, preferred stock, depositary shares, debt securities and warrants that the company may offer in one or more offerings.
The prospectus explains that specific terms, prices and underwriting arrangements will be provided in future prospectus supplements, and that proceeds from any sales are expected to be used for general corporate purposes, including operations, R&D, possible debt repayment and acquisitions.